AR and prostate cancer: Activation of these pathways in patients treated with AR-directed therapies led phenotypically to a process of epithelial–mesenchymal transition (EMT), a significant contributor to prostate cancer progression, development of metastasis, and therapeutic resistance through autocrine or paracrine mechanisms [50].